Venetoclax
Small molecule targets BCL2, MCL1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (9) | US (FDA) | VENCLEXTA | — | 2017-12-20 – 2026-05-20 | fda.gov ↗ |
| Approved | EU (EMA) | Venclyxto | — | 2016-12-04 | europa.eu ↗ |
| Approved | US (FDA) | VENCLEXTA | — | 2016-04-11 | fda.gov ↗ |
Trials 664 · started per year
Also used as a comparator or background therapy in 94 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 129 trials | ||||||
| Phase 1 | NCT07439211 Background | Jul 2026 → Feb 2028 expected | acute myeloid leukemia | Jacqueline Garcia, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07617285 Background | May 2026 → Dec 2027 expected | acute myeloid leukemia | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07177079 Background | Mar 2026 → Dec 2028 expected | acute myeloid leukemia | Kittika Poonsombudlert | Recruiting | No outcome recorded |
| Phase 1 | NCT07374029 Background | Feb 2026 → Oct 2027 expected | acute myeloid leukemia | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT07014462 Background | Sep 2025 → Jun 2029 expected | acute myeloid leukemia | University of Vermont | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06763341 Background | Jul 2025 → Jan 2027 | acute myeloid leukemia | City of Hope Medical Center | Suspended | No outcome recorded |
| Phase 1 | NCT06651229 Background | Mar 2025 → Aug 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06448013 Background | Mar 2025 → Dec 2028 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06397027 Background | Dec 2024 → Dec 2028 expected | refractory hematologic cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06634394 Background | Oct 2024 → Oct 2027 expected | acute myeloid leukemia | Aptevo Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06429449 Background | Jul 2024 → Dec 2026 expected | acute myeloid leukemia, monocytic leukemia | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06372717 Background | Jun 2024 → Mar 2027 expected | acute myeloid leukemia, myelodysplastic syndrome with excess blasts | Apollo Therapeutics Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06152809 Background | Feb 2024 → Nov 2026 expected | acute myeloid leukemia | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05735184 Background | Jul 2023 → Apr 2030 expected | acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, MLL gene rearrangement, myeloid sarcoma | Kura Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05263284 Background | Dec 2022 → Jan 2029 expected | acute myeloid leukemia | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05829226 Background | Dec 2022 → Dec 2025 | acute myeloid leukemia, myelodysplastic syndrome | PureTech | Completed | No outcome recorded |
| Phase 1 | NCT05155709 Background | May 2022 → Apr 2024 | acute myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05001828 Background | Apr 2022 → May 2026 overdue | acute myeloid leukemia | Polaris Group | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05107856 Background | Mar 2022 → Jan 2024 | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myelomonocytic leukemia, follicular lymphoma +3 | Prelude Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT05168202 Background | Jan 2022 → Jul 2024 | acute myeloid leukemia, myelodysplastic syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT04937166 Background | Jan 2022 → Apr 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Kahr Medical | Terminated | No outcome recorded |
| Phase 1 | NCT04748848 Background | Oct 2021 → Mar 2022 | myeloid leukemia | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT04755244 Background | May 2021 → May 2023 | acute myeloid leukemia | ALX Oncology Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04512105 Background | Dec 2020 → Jul 2024 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia | University of California, Irvine | Completed | No outcome recorded |
| Phase 1 | NCT04372433 Background | Sep 2020 → Jan 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04150887 Background | Dec 2019 → May 2027 expected | acute myeloid leukemia | OncoVerity, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04017546 Background | Aug 2019 → Nov 2022 | acute myeloid leukemia, myelodysplastic syndrome | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03113643 Background | Jun 2017 → Sep 2021 overdue | CD4+/CD56+ hematodermic neoplasm, acute myeloid leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT03063944 Background | Mar 2017 → Jan 2024 | acute myeloid leukemia | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/216 trials | ||||||
| Phase 1/2 | NCT07604233 Background | Nov 2026 → Jun 2031 expected | myeloid leukemia | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07294677 Background | Mar 2026 → Mar 2032 expected | leukemia, lymphoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07486726 Background | Mar 2026 → Oct 2027 expected | acute myeloid leukemia | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07028073 Background | May 2025 → May 2027 expected | acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, KIT gene mutation, acute myeloid leukemia, t(16;16)(p13.1;q22) | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06644183 Background | Mar 2025 → Oct 2028 expected | B-cell chronic lymphocytic leukemia | Jennifer R. Brown, MD, PhD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06746519 Background | Dec 2024 → Dec 2025 overdue | acute myeloid leukemia | Chen Suning | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06150040 Background | Sep 2024 → Feb 2025 | acute myeloid leukemia | Centre Leon Berard | Terminated | No outcome recorded |
| Phase 1/2 | NCT06387420 Background | Apr 2024 → Apr 2026 overdue | acute myeloid leukemia | Akeso | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03932318 Background | Mar → Dec 2023 | acute myeloid leukemia | Actinium Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05360160 Background | Oct 2022 → Dec 2026 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05428969 Background | Jun 2022 → Mar 2027 expected | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Faron Pharmaceuticals Ltd | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04988555 Background | Feb 2022 → Jun 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04588922 Background | May 2021 → Dec 2026 expected | hematopoietic and lymphoid cell neoplasm | Sellas Life Sciences Group | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04278768 Background | Jul 2020 → Apr 2026 | acute myeloid leukemia, myelodysplastic syndrome | Curis, Inc. | Suspended | No outcome recorded |
| Phase 1/2 | NCT03867682 Background | Jan 2020 → Nov 2023 | acute myeloid leukemia | Actinium Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT04068597 Background | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT07710534 Comparator | Sep 2026 → Sep 2031 expected | acute myeloid leukemia, myelodysplastic syndrome | Virginia Commonwealth University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07060001 Comparator | Apr 2026 → Dec 2028 expected | acute myeloid leukemia | The Methodist Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06672146 Background | May 2025 → Mar 2027 expected | acute myeloid leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05766514 Comparator | Apr 2025 → Dec 2029 | acute myeloid leukemia, myelodysplastic syndrome | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT06744556 Background | Jan 2025 → Dec 2027 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06783790 Background | Jan 2025 → Dec 2026 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06742515 Background | Oct 2024 → Oct 2026 expected | precursor B-cell acute lymphoblastic leukemia | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07163793 Comparator | Oct 2024 → Oct 2026 expected | acute myeloid leukemia | Northwell Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06532552 Background | Jul 2024 → Aug 2027 expected | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06384261 Background | Jul 2024 → Jan 2027 expected | acute myeloid leukemia | OncoVerity, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06220162 Background | Feb 2024 → Dec 2026 expected | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06109064 Background | Oct 2023 → Feb 2024 | myelodysplastic syndrome | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06105658 Background | Oct 2023 → Feb 2024 | acute myeloid leukemia | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06532058 Background | Aug 2023 → Feb 2025 overdue | acute myeloid leukemia | Changzhou Qianhong Bio-pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05069051 Comparator | Jan 2022 → Jul 2026 overdue | B-cell chronic lymphocytic leukemia | University Hospital Tuebingen | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04905407 Background | Aug 2021 → Aug 2024 | acute myeloid leukemia | Syros Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04778410 Background | Jun 2021 → Mar 2024 | myeloid neoplasm | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT05025098 Background | Jun 2021 → Jun 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | University Hospital, Akershus | Recruiting | No outcome recorded |
| Phase 2 | NCT04812548 Background | May 2021 → May 2023 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04284787 Background | Feb 2021 → Jun 2023 overdue | therapy related acute myeloid leukemia and myelodysplastic syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04146038 Background | Oct 2020 → Oct 2021 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT04150029 Background | Sep 2020 → Oct 2024 | acute myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04501939 Background | Aug 2020 → Jul 2026 overdue | B-cell chronic lymphocytic leukemia | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04016805 Background | Aug 2019 → May 2022 | chronic lymphocytic leukemia/small lymphocytic lymphoma | TG Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07623187 Background | Nov 2026 → May 2031 expected | acute myeloid leukemia | Ipsen | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07581002 Background | Jul 2026 → Jun 2032 expected | acute myeloid leukemia | AbbVie | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07255872 Background | Mar 2026 → Dec 2027 expected | acute myeloid leukemia | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 317 trials | ||||||
| Phase 3 | NCT07478991 Background | Mar 2026 → Apr 2030 expected | acute myeloid leukemia | PETHEMA Foundation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07277231 Comparator | Jan 2026 → Feb 2031 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT07007312 Background | Sep 2025 → Nov 2031 expected | acute myeloid leukemia | Kura Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06943872 Comparator | Jun 2025 → Sep 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT07541755 Background | May 2025 → Jan 2027 expected | T-cell acute lymphoblastic leukemia | Fujian Medical University Union Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06846671 Comparator | Apr 2025 → May 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT06073821 Comparator | Nov 2023 → Feb 2032 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05079230 Background | Jul 2022 → Apr 2024 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT05457361 Comparator | Mar → Dec 2022 | — | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04965493 Background | Sep 2021 → Oct 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Loxo Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04778397 Comparator | Jul 2021 → Mar 2024 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT05264883 Comparator | Mar 2021 → Jun 2023 | acute myeloid leukemia | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04229979 Comparator | Feb 2021 → Dec 2025 overdue | acute myeloid leukemia | Sellas Life Sciences Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03926624 Comparator | Nov 2019 → Jan 2026 | acute myeloid leukemia | Delta-Fly Pharma, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04000698 Background | Oct 2019 → Jul 2022 | acute lymphoblastic leukemia, acute myeloid leukemia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| Phase 3 | NCT02993523 Comparator | Feb 2017 → Dec 2021 overdue | acute myeloid leukemia | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02665065 Comparator | Jun 2016 → Jun 2022 overdue | acute myeloid leukemia | Actinium Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04790045 Background | Nov 2023 → Dec 2026 expected | B-cell chronic lymphocytic leukemia | Paolo Ghia | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07244367 Comparator | Sep 2025 → Sep 2026 expected | acute myeloid leukemia | Sohag University | Recruiting | No outcome recorded |
| — | NCT06481241 Background | Jun 2024 → Jun 2026 overdue | adult acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT03123029 Background | — | acute myeloid leukemia, amyloidosis, chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell leukemia +1 | AbbVie | Available | No outcome recorded |
| — | NCT03592576 Background | — | acute lymphoblastic leukemia, lymphoblastic lymphoma, myelofibrosis | AbbVie | No longer available | No outcome recorded |
Press releases naming this drug 93 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | AbbVie | AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results abbvie.com ↗ |
| 2026-05-29 | AbbVie | AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2026-02-20 | AstraZeneca | Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting astrazeneca.com ↗ |
| 2026-02-20 | AbbVie | U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2025-07-29 | AbbVie | AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2024-12-08 | AstraZeneca | Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukaemia, with 77% of patients progression free at three years in AMPLIFY Phase III trial astrazeneca.com ↗ |
| 2024-07-29 | AstraZeneca | Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial astrazeneca.com ↗ |
| 2023-12-10 | AbbVie | ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH abbvie.com ↗ |
| 2023-09-29 | AbbVie | AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma abbvie.com ↗ |
| 2023-06-09 | AbbVie | AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients abbvie.com ↗ |
| 2022-12-10 | AbbVie | ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH abbvie.com ↗ |
| 2022-06-10 | AbbVie | New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment abbvie.com ↗ |
| 2021-12-12 | AbbVie | ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH abbvie.com ↗ |
| 2021-11-04 | AbbVie | ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH abbvie.com ↗ |
| 2021-07-21 | Roche Global Development | FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes roche.com ↗ |
| 2021-07-21 | AbbVie | Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS) abbvie.com ↗ |
| 2021-06-12 | AbbVie | IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study abbvie.com ↗ |
| 2021-06-11 | Roche Global Development | Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia roche.com ↗ |
| 2021-06-11 | AbbVie | New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment abbvie.com ↗ |
| 2021-06-07 | AbbVie | CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2021-05-25 | Roche Global Development | European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy roche.com ↗ |
| 2021-05-25 | AbbVie | AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy abbvie.com ↗ |
| 2021-04-23 | AbbVie | AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy abbvie.com ↗ |
| 2020-12-05 | Roche Global Development | Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia roche.com ↗ |
| 2020-12-05 | AbbVie | IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2020-12-05 | AbbVie | AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2020-10-19 | Roche Global Development | Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia roche.com ↗ |
| 2020-10-16 | AbbVie | VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML) abbvie.com ↗ |
| 2020-08-12 | AbbVie | New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients abbvie.com ↗ |
| 2020-06-13 | Roche Global Development | Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 roche.com ↗ |
| 2020-06-13 | AbbVie | VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients abbvie.com ↗ |
| 2020-03-23 | Roche Global Development | Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia roche.com ↗ |
| 2020-03-23 | AbbVie | AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) abbvie.com ↗ |
| 2020-03-12 | Roche Global Development | European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia roche.com ↗ |
| 2020-03-12 | AbbVie | AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2020-02-28 | AbbVie | AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML) abbvie.com ↗ |
| 2020-01-31 | AbbVie | AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2019-12-08 | Roche Global Development | New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia roche.com ↗ |
| 2019-12-08 | AbbVie | New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2019-12-07 | AbbVie | IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2019-06-24 | AbbVie | AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality abbvie.com ↗ |
| 2019-06-04 | Roche Global Development | Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine roche.com ↗ |
| 2019-06-04 | AbbVie | AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2019-05-16 | Roche Global Development | Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia roche.com ↗ |
| 2019-05-15 | AbbVie | AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients abbvie.com ↗ |
| 2019-03-19 | AbbVie | AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program abbvie.com ↗ |
| 2019-03-07 | Roche Global Development | Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions roche.com ↗ |
| 2019-03-07 | AbbVie | AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients abbvie.com ↗ |
| 2018-12-04 | Roche Global Development | New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia roche.com ↗ |
| 2018-12-01 | AbbVie | AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course abbvie.com ↗ |
| 2018-11-21 | Roche Global Development | Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy roche.com ↗ |
| 2018-11-21 | AbbVie | AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy abbvie.com ↗ |
| 2018-11-20 | AbbVie | AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition abbvie.com ↗ |
| 2018-11-01 | Roche Global Development | Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities roche.com ↗ |
| 2018-11-01 | Roche Global Development | Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia roche.com ↗ |
| 2018-11-01 | AbbVie | AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy abbvie.com ↗ |
| 2018-10-31 | AbbVie | AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2018-09-21 | AbbVie | AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy abbvie.com ↗ |
| 2018-09-11 | AbbVie | Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label abbvie.com ↗ |
| 2018-07-12 | AbbVie | AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy abbvie.com ↗ |
| 2018-06-15 | AbbVie | AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress abbvie.com ↗ |
| 2018-06-11 | Roche Global Development | Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia roche.com ↗ |
| 2018-06-08 | AbbVie | AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy abbvie.com ↗ |
| 2018-06-03 | AbbVie | Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2018-05-31 | AbbVie | AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress abbvie.com ↗ |
| 2017-12-12 | Roche Global Development | Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia roche.com ↗ |
| 2017-12-12 | AbbVie | AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint abbvie.com ↗ |
| 2017-11-21 | AbbVie | Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients abbvie.com ↗ |
| 2017-09-18 | Roche Global Development | Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan roche.com ↗ |
| 2017-09-18 | AbbVie | AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2017-06-23 | Roche Global Development | Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers roche.com ↗ |
| 2017-06-23 | AbbVie | AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European Hematology Association (EHA) Annual Congress abbvie.com ↗ |
| 2017-06-12 | AbbVie | AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress abbvie.com ↗ |
| 2016-12-08 | AbbVie | European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO™ (venetoclax) Monotherapy for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia abbvie.com ↗ |
| 2016-10-14 | AbbVie | AbbVie Receives CHMP Positive Opinion for VENCLYXTO™ (venetoclax) Tablets for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia abbvie.com ↗ |
| 2016-07-28 | AbbVie | AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma abbvie.com ↗ |
| 2016-06-09 | AbbVie | AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine Venetoclax abbvie.com ↗ |
| 2016-04-12 | Roche Global Development | Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia roche.com ↗ |
| 2016-04-11 | AbbVie | AbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion abbvie.com ↗ |
| 2016-02-26 | AbbVie | AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) abbvie.com ↗ |
| 2016-01-28 | AbbVie | Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy abbvie.com ↗ |
| 2016-01-20 | AbbVie | AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2016-01-12 | AbbVie | U.S. and European Regulators Accept Applications for AbbVie's Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2015-12-06 | AbbVie | AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion abbvie.com ↗ |
| 2015-12-06 | AbbVie | AbbVie Announces New England Journal of Medicine Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2015-08-12 | AbbVie | Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Primary Endpoint abbvie.com ↗ |
| 2015-06-12 | AbbVie | Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia abbvie.com ↗ |
| 2015-05-31 | AbbVie | AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting abbvie.com ↗ |
| 2015-05-06 | AbbVie | Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation abbvie.com ↗ |
| 2014-12-07 | AbbVie | AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting abbvie.com ↗ |
| 2014-05-31 | AbbVie | AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting abbvie.com ↗ |
| 2013-06-17 | AbbVie | AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting abbvie.com ↗ |
| 2013-06-03 | AbbVie | AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting abbvie.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 777 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | venetoclax | “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗744“Venetoclax, the first highly selective BCL-2 inhibitor available globally, is a BH3 mimetic that selectively binds to the BCL-2 protein, displacing and releasing pro-apoptotic...” NCT05909293 ↗ “This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with...” NCT02203773 ↗ “Venetoclax 400 mg, orally, days 1-28 (the dose of Venetoclax should be adjusted according to the drug dosage instructions/guidelines when combined with CYP3A4 inhibitors); AZA:...” NCT07425782 ↗ “A Single-arm, Single-center Clinical Trial Evaluating the Efficacy and Safety of a Regimen Combining Chidamide With Venetoclax, Azacitidine, and Homoharringtonine in the...” NCT07643636 ↗ “This study aims to evaluate the effectiveness and safety of Venetoclax and Decitabin based conditioning regimen followed with post-HSCT Decitabin maintenance therapy in TP53...” NCT05528354 ↗ “After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to...” NCT06450145 ↗ “For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1.” NCT05025098 ↗ “Venetoclax (VEN) is a BCL-2 inhibitor that can restore activation of apoptosis in malignant cells, the survival of which often depends on dysregulation of this pathway.” NCT04609826 ↗ “Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation” NCT05870995 ↗ “This phase 1b study evaluated safety and efficacy of acalabrutinib, venetoclax, and rituximab (AVR) in treatment-naive mantle cell lymphoma (TN MCL).” PMID 38781315 ↗ Sep 2024 “BACKGROUND: Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma.” PMID 29590547 ↗ Mar 2018 “Azacitidine +Selinexor ± venetoclax were administered (Selinexor: 60mg/ week, qw*4 weeks; azacitidine: 100mg/m2*d1-d7; venetoclax, 100mg d1-14).” NCT07632170 ↗ “Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.” NCT05001828 ↗ “Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2” NCT07214064 ↗ “Targeted therapies such as venetoclax (VEN) (Bcl-2 inhibitor) have revolutionized the treatment of chronic lymphocytic leukemia (CLL).” PMID 37166997 ↗ Jul 2023 “5. Venetoclax is administered orally with a dose ramp-up schedule: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3 through 14.” NCT07512700 ↗ “the XAB regimen: a chemotherapy-free or low-dose chemotherapy regimen containing selinexor (X), azacitidine (A), and venetoclax (B)” NCT07236931 ↗ “Bugitinib orally once daily, Venetoclax orally once daily with dose escalation to target dose, and Cytarabine intravenously daily.” NCT07563179 ↗ “A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia” NCT07423104 ↗ “To evaluate the safety and efficacy of Venetoclax plus IM2 regimen for relapsed and refractory T lymphoblastic lymphoma/leukemia.” NCT05576532 ↗ “Venetoclax 100mg day 1, 200mg day 2, 400mg days 3-28 Azacitidine 75mg/m² days 1-7 Avapritinib orally on days 8-21 (28-day cycle)” NCT07028073 ↗ “Venetoclax: Cycle 1: Dose ramp-up: 100 mg po on Day 1, 200 mg po on Day 2, then 400 mg po once daily from Day 3 to Day 28.” NCT07259707 ↗ “Venetoclax is a selective BCL-2 inhibitor, which has antitumor activity against a variety of hematological malignancies.” NCT05809167 ↗ “Venetoclax is a selective BCL-2 inhibitor, which has antitumor activity against a variety of hematological malignancies.” NCT05823714 ↗ “Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.” PMID 33181832 ↗ Feb 2021 “mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven)” NCT06329999 ↗ “Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)” NCT05833438 ↗ “The selective Bcl-2 inhibitor venetoclax (ABT-199) were assessed in women with systemic lupus erythematosus.” PMID 28691866 ↗ Jul 2017 “Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.” NCT05657639 ↗ “Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14.” NCT06810791 ↗ “HVA regimen: Venetoclax: 100 mg on day 1, 200 mg on Day 2, 400 mg per day from Day 3 to Day 14;” NCT07517510 ↗ “Oral Venetoclax: 8-day schedule（100 mg on day 4, 200 mg on day 5, and 400 mg/day on days 6-11）” NCT07108530 ↗ “To identify the dose of venetoclax (Bcl-2 inhibitor GDC-0199) that can be safely administered” NCT02427451 ↗ “whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy” NCT02781883 ↗ “Participants will receive therapy of venetoclax and CAG regimen (Ara-C, Acla and C C-GSF)” NCT05918198 ↗ “Venetoclax (VEN) 8-day ramp-up: Day 1: 100 mg, Day 2: 200 mg, Days 3-8: 400 mg/day” NCT07059156 ↗ “Venetoclax: oral administration, specified dosage and schedule for induction cycle” NCT07664839 ↗ “All patients receive azacytidine and venetoclax as leukemia debulking treatment” NCT04904237 ↗ “Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2” PMID 26707935 ↗ Dec 2015 “treated with BCL-2 inhibitor venetoclax at a dose of 400mg per day for 14 days” NCT04424147 ↗ “Patients obtain the standard of care: combination rituximab and venetoclax” NCT05069051 ↗ “Venetoclax + demethylating agents (HMA) , Venetoclax + HMA + other drugs” NCT07091006 ↗ “The second cycle would be the combination of Blina and Venetoclax(VEN).” NCT06742515 ↗ “Venetoclax 100mg on Day 1, 200mg on Day 2, and 400mg on Day 3 to Day 14” NCT07028086 ↗ “venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28” NCT05478512 ↗ “Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination)” NCT05774886 ↗ “GC Type: Glofitamab + BCL-2 inhibitor (e.g., Lisaftoclax/Venetoclax)” NCT07602322 ↗ “Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28)” NCT06532552 ↗ “venetoclax, an oral selective small-molecule BCL-2 inhibitor” NCT07541755 ↗ “Venetoclax Combined With Azacitidine Plus Homoharringtonine” NCT05457361 ↗ “Venetoclax (VEN) 100mg d1,200mg d2,400mg d3 to d14, orally.” NCT05584761 ↗ “Venetoclax+hypomethylating agent (decitabine, azacitidine)” NCT06713837 ↗ “Venetoclax: 600 mg/m² orally once daily on days -10 to -5.” NCT07583888 ↗ “Venetoclax administered with a target dose of 200 mg/day.” NCT07617285 ↗ “Venetoclax (in combination with a hypomethylating agent)” NCT02665065 ↗ “100 mg QD of idelalisib + 100 mg QD of venetoclax” NCT03639324 ↗ “Venetoclax 400mg per dose, once daily for 4 weeks” NCT06737523 ↗ “Venetoclax (B): 400 mg, orally, once daily (QD)” NCT07521124 ↗ “Venetoclax 400mg per day from day 1 to day 7” NCT07537257 ↗ “Venetoclax 400 mg PO daily on Days 1-28” NCT07172204 ↗ “* Cytarabine * Venetoclax * Daratumomab” NCT04000698 ↗ “venetoclax (Bcl-2 inhibitor)” NCT06046313 ↗ “Venetoclax (VEN): Day1-10” NCT07117422 ↗ “ABT-199 (venetoclax)” NCT04171791 ↗ “Drug: Venetoclax” NCT07014917 ↗ “Drug: Venetoclax” NCT03886649 ↗ |
| Known as | ABBVIE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗ |
| Known as | ABT-0199 | “ABT-0199” NCT05600894 ↗ |
| Known as | ABT-199 | “The aim of the study is to improve long term results of R-BAC, consolidating patients with high-risk (HR) features (defined as: elevated Ki67 and/or blastoid cytology and/or...” NCT03567876 ↗26“This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with...” NCT02203773 ↗ “Moreover, the BCL2 antagonist venetoclax (previously GDC-0199/ABT-199), tested as a single agent in relapsed / refractory CLL patients, showed striking activity with tumor...” NCT02758665 ↗ “Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety...” PMID 27233802 ↗ May 2016 “Phase II Single-arm "Window-of-opportunity" Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)” NCT02987400 ↗ “Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL” NCT03836261 ↗ “Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)” NCT03466294 ↗ “Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)” NCT02756611 ↗ “administration of the Bcl-2 inhibitor, ABT-199 (Venetoclax), showed marked efficacy in preclinical models of IPF” NCT05976217 ↗ “Venetoclax (ABT-199/GDC-0199, VEN) is a highly selective, oral B-cell lymphoma 2 (BCL-2) inhibitor” NCT04824924 ↗ “the BCL2 inhibitor ABT199/venetoclax” PMID 35154579 ↗ Feb 2022 “ABT199” NCT05600894 ↗ |
| Known as | C45H50CLN7O7S | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗ |
| Known as | CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPY | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗ |
| Known as | GDC-0199 | “Moreover, the BCL2 antagonist venetoclax (previously GDC-0199/ABT-199), tested as a single agent in relapsed / refractory CLL patients, showed striking activity with tumor...” NCT02758665 ↗6“Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety...” PMID 27233802 ↗ May 2016 “A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion” NCT01889186 ↗ “Venetoclax (ABT-199/GDC-0199, VEN) is a highly selective, oral B-cell lymphoma 2 (BCL-2) inhibitor” NCT04824924 ↗ “Venetoclax (ABT-199/GDC-0199) is being developed in collaboration between AbbVie and Genentech.” PMID 34599139 ↗ Oct 2021 “[14C]ABT-199 (GDC-0199)” NCT02095574 ↗ “GDC0199” NCT05600894 ↗ |
| Known as | GDC-199 | “a BCL-2 inhibitor (GDC-199, venetoclax)” NCT03276468 ↗ |
| Known as | LD-VEN | “short duration of "low-dose" venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd)” NCT05431257 ↗ |
| Known as | RG7601 | “RG7601” NCT05600894 ↗ |
| Known as | UNII-N54AIC43PW | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗ |
| Known as | VEN | “The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN...” NCT03295240 ↗41“Based on the efficacy data of venetoclax (VEN)-based treatment in NPM1mut AML older patients, we retrospectively analysed the off-label combination of VEN plus azacitidine...” PMID 37226312 ↗ May 2023 “This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA)...” NCT07581002 ↗ “Omacetaxine mepesuccinate (OM), a semisynthetic analog of homoharringtonine, has been shown to be lethal to RUNX1 mut AML cells in vitro through reduction of MCL1 and BCL-XL,...” PMID 40979071 ↗ Jul 2025 “Functional small-molecule screening of primary acute myeloid leukemia (AML) samples identified ex vivo synergy between the JAK1/2 inhibitor, ruxolitinib (Rux), and venetoclax...” PMID 42007254 ↗ Feb 2026 “Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN...” PMID 41796974 ↗ Mar 2026 “• Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once...” NCT07007949 ↗ “Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acute myeloid leukemia (AML), but its integration with the 7+3 regimen remains underexplored.” PMID 39919267 ↗ Apr 2025 “Venetoclax (VEN) is a BCL-2 inhibitor that can restore activation of apoptosis in malignant cells, the survival of which often depends on dysregulation of this pathway.” NCT04609826 ↗ “VEN: 400 mg, orally, days 1-28 (Venetoclax dosage must be adjusted per prescribing information/guidelines based on concomitant use of CYP3A4 inhibitors)” NCT07425782 ↗ “The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML) therapy.” PMID 36892565 ↗ Jun 2023 “the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax (Ven), resulting in significantly reduced leukemia burden and enhanced survival” PMID 39437546 ↗ Jan 2025 “Venetoclax (VEN), a selective BCL-2 inhibitor, has previously been evaluated with bendamustine-based chemoimmunotherapy.” PMID 40355425 ↗ May 2025 “Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)” NCT05833438 ↗ “5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission.” NCT04062266 ↗ “The induction therapy is a combination of Venetoclax(Ven), Homoharringtonine(HHT) , Cytarabine and G-CSF.” NCT06742463 ↗ “Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14.” NCT06810791 ↗ “Venetoclax (ABT-199/GDC-0199, VEN) is a highly selective, oral B-cell lymphoma 2 (BCL-2) inhibitor” NCT04824924 ↗ “Preclinical data in both B- and T-ALL suggests synergy of venetoclax (VEN) with vincristine (VCR).” PMID 39415930 ↗ Aug 2024 “Adding venetoclax (VEN) to ibrutinib (IBR) has shown synergy in preclinical MCL models.” PMID 34700344 ↗ Mar 2022 “Venetoclax (VEN) 8-day ramp-up: Day 1: 100 mg, Day 2: 200 mg, Days 3-8: 400 mg/day” NCT07059156 ↗ “Venetoclax (VEN)+Azacytidine (AZA) Followed by Modified BUCY Conditioning Regimen” NCT05809167 ↗ “Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly” NCT04476199 ↗ “Venetoclax (Ven) is an oral, selective inhibitor of B-cell lymphoma 2 (Bcl-2).” NCT05660473 ↗ “Venetoclax (VEN): 100mg on day 1, 200mg on day 2, and 400mg on days 3-8.” NCT05893472 ↗ “The second cycle would be the combination of Blina and Venetoclax(VEN).” NCT06742515 ↗ “Venetoclax (Ven): oral once daily (100 mg d1, 200 mg d2, 400 mg d3-28);” NCT05264883 ↗ “Venetoclax (VEN) was administered at 400mg/day on days -10 to -4.” NCT07052422 ↗ “Venetoclax (VEN) 400 milligrams (mg), taken by mouth once weekly” NCT07710534 ↗ “Venetoclax (VEN) was administered at 400mg/day on days 1 to 28.” NCT07264010 ↗ “Dose Expansion of IO-202 plus Azacitidine + Venetoclax (Ven)” NCT04372433 ↗ “Venetoclax (VEN) 100mg d1,200mg d2,400mg d3 to d14, orally.” NCT05584761 ↗ “Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA)” NCT06852222 ↗ “Venetoclax (VEN) and DEC have synergistic effect.” NCT05528354 ↗ “Venetoclax (VEN): Day1-10” NCT07117422 ↗ “Drug: VEN (Venetoclax)” NCT07159620 ↗ “Venetoclax (VEN)” NCT07635485 ↗ “Venetoclax (VEN)” NCT06696183 ↗ “Venetoclax (Ven)” NCT04778410 ↗ “Venetoclax (VEN)” NCT06651229 ↗ “Venetoclax (VEN)” NCT05453903 ↗ “VEN (Venetoclax)” NCT07047183 ↗ |
| Known as | Venclexta | “Venetoclax 100 MG Oral Tablet [Venclexta]” NCT04802590 ↗ |
| Known as | Venclyxto | “The drug venetoclax (Venclyxto) is an inhibitor of BCL-2 (B Cell Lymphoma-2), a key factor involved in the regulation of programmed cell death.” NCT07481175 ↗2“Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2” NCT07214064 ↗ “Venclyxto” NCT05600894 ↗ |
| Known as | VENETOCLAX (ABT-199) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗ |
| Known as | Venetoclax (ABT-199, GDC-0199) | “Venetoclax (ABT-199, GDC-0199)” NCT05362942 ↗ |
| Known as | VENETOCLAXVENCLEXTAABT-199A-12314-[4-[[2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL]METHYL]PIPERAZIN-1-YL]-N-[[3-NITRO-4-[[(TETRAHYDRO-2H-PYRAN-4-YL)METHYL]AMINO]PHENYL]SULFONYL]-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗ |
| Action | Inhibit | “the oral BCL-2 inhibitor venetoclax” PMID 34083230 ↗ Jun 2021 |
| Modality | Small molecule | “venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor” PMID 27520294 ↗ Aug 2016 |
| Route | Oral | “venetoclax PO QD” NCT00501826 ↗ |
| Target | BCL2 | “it targets BCL2, a protein central to the survival of CLL cells.” PMID 26639348 ↗ Dec 2015 |